AptarGroup heads into its third-quarter report with a story that sounds better than its stock chart. Management told investors three months ago that the worst of the emergency-medicine destock was behind it, that core pharma was growing again and that beauty and closures margins were mending. The market has not bought it. Shares have fallen 8.5% since that report while the S&P 500 gained 3.3%. That leaves this release, the first under new CEO Gael Touya, needing to prove the inflection is real.
The bar itself is not demanding. Consensus calls for adjusted EPS of $1.46 on revenue of about $976.2 million, a 9.9% drop in earnings from last year's $1.62 on sales growth of just 1.6%. Management guided to $1.45 to $1.53, so the Street sits near the low end of that range rather than in the middle. That is a cautious stance. It suggests analysts are building in some cushion for the last chunk of the emergency-medicine headwind, the effect of currency moves, and possible slippage during the leadership handoff. Aptar has some credibility here. Its second-quarter EPS of $1.42 beat its own $1.32 to $1.40 guide, and the beat came from operations despite about two cents of currency drag.
The central mechanical question is how cleanly the remaining emergency-medicine drag passes through. Management said roughly two-thirds of the roughly $65 million full-year headwind landed in the first half. Most of the rest falls in the third quarter, with the effect fully washing out by the fourth. That high-margin mix loss pushed pharma's EBITDA margin down 180 basis points to 33.6% last quarter and dragged the company margin to 20.7% from 22.6%. A third-quarter result that shows the year-over-year margin gap narrowing, even modestly, would support the claim that Q2 was the trough. A gap that stays as wide or wider would undercut it.
Beneath that, the underlying pharma engine has to keep running. Pharma excluding emergency medicine grew 8% in the second quarter. Injectables rose 9% on GLP-1, biologics and vaccine demand, and consumer healthcare jumped 15% after much smaller gains in the two prior quarters. Holding high single-digit core growth would validate Touya's reaffirmation of the 7% to 11% long-term pharma target. Consumer healthcare will likely cool from that 15% pace, so the useful question is whether it stays solidly positive rather than whether it repeats. Updates on the pipeline would add color, but they matter less to this quarter's numbers. That includes the nitrosamine-reduction patent, the inhaled and nasal GLP-1 filings and FDA's easing of generic inhaled guidance.
The consumer side is where the narrative is most fragile. Beauty EBITDA margin climbed from 10.2% to 11.1% to 12.2% over three quarters, and closures reached 14.9%. Investors should want a fourth step up in beauty, which would mean Middle East input-cost inflation is finally being passed through to customers. Last quarter that pass-through lag cost roughly 80 to 90 basis points. Beauty Americas remains the soft spot, with North American operational problems and fresh weakness in Brazil. New management declined to set a timeline for fixing it. Any concrete plan from Touya would be a meaningful signal. Another quarter of vague commitments would feed the skepticism already priced into the stock. A tax rate that stepped up to 23.7% also limits how much operating gains reach EPS.
Sentiment has drifted from mildly bullish to mildly bearish, and the stock sits just below its 200-day moving average at $125.77. That puts it closer to the bottom of its post-earnings range of $118.34 to $139.57 than the top. Expectations, in other words, are subdued. The report hinges on whether Aptar can show that reported margins are turning with the underlying business. If the last emergency-medicine hit lands as planned and beauty margins keep climbing, the turning-point narrative holds. If not, the market's doubts will look justified.